View
234
Download
2
Category
Preview:
Citation preview
mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab alone or with erlotinib in 1st line treatment of patients with
metastatic colorectal cancer : Interim safety analysis of DREAM study.
C. Tournigand1, B. Samson2, W. Scheithauer3, C. Louvet1, T. Andre4, G. Lledo5, J. Latreille2, F. Viret6, B. Chibaudel7, A. de Gramont1;
1Hopital Saint Antoine, Paris, France; 2Hopital Charles Lemoyne, Greenfield Park, QC, Canada; 3University of Vienna, Vienna, Austria; 4Hopital Pitié-Salpetrière, Paris, France;
5Hopital Privé Jean Mermoz, Lyon, France; 6Institut Paoli Calmette, Marseille, France; 7Gercor, Paris, France
ABSTRACT
Background : Anti-VEGF or EGFR inhibitors demonstrated clinical activity in combination with chemotherapy (CT) in mCRC. The DREAM trial compares, after an induction CT of 6 cy of FOLFOX-Bev or XELOX-Bev, a maintenance with Bev +/- Erlotinib. We report here a pre-planned safety analysis of induction (I) and maintenance (M) phase for the first 200 patients.
Methods : Patients (pts) with untreated mCRC were randomly assigned to 2 arms (I): mFOLFOX+Bev (n=100), or mXELOX+Bev (n=100). mFOLFOX-Bev: LV 400 mg/m², Oxaliplatin (ox) 100 mg/m², B 5 mg/kg d1, 5FU ci 2.4g/m² 46h, q2w, mXELOX-Bev: Ox 100 mg/m² d1, capecitabine 2.5 g/m² d1-7, Bev 5mg/kg, q2w. To date, 117 pts with a disease control after 6 cy have had a 2nd randomisation (M): Bev alone (7.5 mg/kg q3w, n=56) or Bev+Erlotinib 150 mg/d (n=61) until PD.
Results : Pts characteristics were: sex: 124M/76F, median age: 62.4 years (26-80), primary tumors: colon 152, rectum 53, synchronous metastases: 150 pts, > 1 metastase site: 115, PS 0/1: 134/66, Alk. Ph.>UNL: 87 pts, and LDH>UNL: 88pts. For I, 92 pts in mFOLFOX-Bev and 93 in XELOX-Bev were evaluable for toxicity (tox). Tox (%) for mFOLFOX-Bev/XELOX-Bev were: any toxicity grade (gr) 3 or 4: 21/30; neutropenia gr 3 6/1, gr 4 0/2; febrile neutropenia gr 3 1/1, gr 4 0/1; thrombopenia gr 3 0/1, gr 4 0/2; anemia gr 2 8/15, gr 3 2/1; nausea gr 2 17/15, gr 3 4/6; vomiting gr 2 10/12, gr 3 2/5; mucositis gr 2 6/6, gr 3 0/4; diarrhea gr 2 8/12, gr 3 5/20, gr 4 0/1; neuropathy gr 2 23/17 gr 3 3/1; HFS gr 2 0/7, gr 3 0/2; hypertension gr 2 2/3, gr 3 1/0; proteinuria gr 2 1/5; SAEs 14/25.
For Maintenance, 56 pts in B and 61 pts in Bev+Erlotinib were evaluable. Tox (% Bev/Bev+Erlotinib) were: neutropenia gr 2 0/3; thrombopenia gr 2 2/0; nausea gr 2 2/2, gr 3 2/0; vomiting gr 3 2/0; mucositis gr 2 2/3; diarrhea gr 2 0/6, gr 3 2/6; skin tox gr 1 9/31, gr 2 0/38, gr 3 0/16, gr 4 0/2; proteinuria gr 2 5/5; hypertension gr 1 9/15, gr 2 3/8, gr 3 3/0.
Conclusion : This interim safety analysis demonstrated that induction with mFOLFOX-Bev or XELOX-Bev as well as maintenance with Bev or Bev + Erlotinib appears to be well-tolerated, without unexpected side effects. The DREAM study is ongoing, with a prolonged induction phase of 6 months (3 mo with ox then 3 mo with fluoropyrimidines-B) before randomisation for maintenance therapy.
INTRODUCTIONOPTIMOX1 and 2 studies validated the "stop and go strategy" or stopping oxaliplatin after 6 cycles in metastatic colorectal cancer. (Tournigand et al. JCO 2006, Maindrault-Goebel, ASCO 2007)
Bevacizumab increases PFS in combination with first-line chemotherapy. (Saltz et al., JCO 2008)
A modified XELOX regimen (7 days on, 7 days off) demonstrated a good therapeutic ratio (Scheithauer et al., JCO 2003)
Erlotinib is an orally active, selective inhibitor of HER1/EGFR tyrosine-kinase. In preclinical models, administration of EGFR inhibitors in combination with antiangiogenic agents has shown additive cytotoxicity. (Ciardello et al. Clinical Cancer Res 2000, 2004)
mFOLFOX7 +bevacizumab
x6 cycles
mFOLFOX7 +bevacizumab
x6 cycles
mXELOX + bevacizumab
X6 cycles
mXELOX + bevacizumab
X6 cycles
N=640
RRAANNDDOOMMIISSAATTIIOONN
RRAANNDDOOMMIISSAATTIIOONN
bevacizumab bevacizumab + erlotinib+ erlotinibuntil PDuntil PD
bevacizumab bevacizumab + erlotinib+ erlotinibuntil PDuntil PD
DREAM study (Phase III)
bevacizumabbevacizumabuntil PDuntil PD
bevacizumabbevacizumabuntil PDuntil PD
RRAANNDDOOMMIISSAATTIIOONN
RRAANNDDOOMMIISSAATTIIOONN
PR PR or or SDSD
INDUCTION MAINTENANCE
LV 400 5-FU 2.4 g/m²mFolfox7oxali 100
D1 D1 D2 D2
Capecitabine 2500 mg/m²/dmXELOXoxali 100
D1 D1 D7 D7
bev. 5
bev. 5
erlotinib
Every 2 weeks
Every 2 weeks
CHEMOTHERAPYIN
DU
CT
ION
MA
INT
EN
AN
CE
bev. 7.5 Every 3 weeks
Erlotinib 150 mg/day, continuous
Inclusion criteriaHistologically proven adenocarcinoma of colon or rectum.
Unresectable metastatic disease, i.e. non suitable for complete carcinological surgical resection.
No previous chemotherapy and/or immunotherapy for metastatic disease.
In case of previous adjuvant chemotherapy, progression-free interval from end of previous adjuvant chemotherapy > 6 months (2 years if oxaliplatin or CPT11 received as adjuvant therapy)
Measurable lesion or non measurable lesions
Age 18 years - 80 years.
WHO (ECOG) performance status 0-2 .
Hematological status:
Neutrophils 1,5 109/L
Platelets 100 109/L
Haemoglobin > 9 g/dL (may be transfused to maintain or exceed this level)
International Normalized Ratio (INR) 1.5; APPT <1.5 x UNL
Adequate renal function, No proteinuria at baseline.
Hepatic function: Total bilirubin < 1.5 x upper normal limit (UNL), ALP :< 3 x ULN
Neurologic status: no peripheral sensory neuropathy (NCI grade 0).
Patients Characteristicsn=200
Sex ratio 124 M / 76 F
Median Age 62.4 years (26-80yrs)
WHO PS 0 vs 1 134 vs 66 pts
Colon vs rectum 152 vs 53 pts
Synchronous mets150 pts
>1 metastatic site 115 pts
Alk Phosphatase >UNL 87 pts
LDH>UNL 88 pts
INDUCTION CHEMOTHERAPY Hematologic toxicity (grade 3-4)
FOLFOX-BevacizumabN=92
%
XELOX-BevacizumabN=93
%
Neutropenia grade 3 grade 4
60
12
Thrombocytopenia grade 3 grade 4
00
12
Anemia grade 3 grade 2
28
115
Febrile neutropenia 1 2
INDUCTION CHEMOTHERAPY Non-Hematologic toxicity
FOLFOX-Bevacizumab N=92
%
XELOX-BevacizumabN=93
%
Nausea grade 3 grade 2
4 17
615
Vomiting grade 3 grade 2
210
512
Mucositis grade 3 grade 2
06
46
Diarrhea grade 3-4 grade 2
58
2112
Neuropathy grade 3 grade 2
323
117
Hand-Foot syndrome grade 3 grade 2
00
27
FOLFOX-Bevacizumab
N=92%
XELOX-Bevacizumab
N=93%
HTA grade 3 grade 2
12
03
Proteinuria grade 3 grade 2
01
05
INDUCTION CHEMOTHERAPY Bevacizumab-related toxicity
BevacizumabN=56
%
Bevacizumab – ErlotinibN=61
%
Nausea grade 3 grade 2
22
02
Vomiting grade 3 2 0
Mucositis grade 2 2 3
Diarrhea grade 3 grade 2
02
66
Neutropenia grade 2 0 3
Thrombocytopenia grade 2 2 0
MAINTENANCE : toxicity
MAINTENANCE toxicity
Bevacizumab N=56
%
Bevacizumab – ErlotinibN=61
%
Cutaneous toxicity Grade 1 Grade 2 Grade 3 Grade 4
9000
3138162
HTA Grade 1 Grade 2 Grade 3
933
1580
Proteinuria Grade 2 5 5
Conclusion
Acknowledgement : Roche for financial support of the DREAM study
Both mFOLFOX7-bevacizumab and mXELOX-bevacizumab are well tolerated as first-line therapy in metastatic colorectal cancer
As expected, the main toxicity of the association of bevacizumab and erlotinib is cutaneous (18% grade 3-4)
Considering the recent results of OPTIMOX2, a prolongation of the maintenance phase from 3 months to 6 months before maintenance therapy has been adopted in the study
KRAS status will be available for all patients
18%verif
mFOLFOX7 +bevacizumab
X6 cycles
mFOLFOX7 +bevacizumab
X6 cycles
mXELOX + bevacizumab
x6 cycles
mXELOX + bevacizumab
x6 cycles
bevacizumab bevacizumab + erlotinib+ erlotinibuntil PDuntil PD
bevacizumab bevacizumab + erlotinib+ erlotinibuntil PDuntil PD
DREAM study (Phase III)DREAM study (Phase III)New designNew design
bevacizumabbevacizumabuntil PDuntil PD
bevacizumabbevacizumabuntil PDuntil PD
RANDOMISATION
RANDOMISATION
CR2 or
PR or SD
mLV5FU2 +bevacizumab
3 months
mLV5FU2 +bevacizumab
3 months
FOLFIRI – bevacizumab 6 monthsFOLFIRI – bevacizumab 6 months
Or1
1 investigator’s choice
Or1
2without surgery
REGISTRATION
REGISTRATION
• Inclusion criteria :– IP 0 – 2– Alk Ph < 5xN
capecitabine +bevacizumab
3 months
capecitabine +bevacizumab
3 months
Recommended